EUVIMEDEUVIMED entdecken
Vergleichsstudie

Improvement of Transmural Inflammation With Adalimumab Versus Immunomodulator Maintenance Therapy in Pediatric Crohn’s Disease: Single-Center Prospective Evaluation Using the Pediatric Inflammatory Crohn’s Magnetic Resonance Enterography Index

Luca Scarallo iD, Hayley E McKay, Rilla Schneider, Amanda Ricciuto, Thomas D Walters, Mary-Louise C Greer, Anne M Griffiths, Peter C Church iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae227 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Luca Scarallo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Nutrition Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Adalimumab, Crohn Disease, Magnetic Resonance Imaging, Inflammation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Abbvie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Transmural healing, including as assessed by magnetic resonance enterography (MRE) has been associated with long-term favorable outcomes in Crohn’s Disease (CD), but data concerning MRE improvement and normalization with therapy are sparse. We performed a prospective longitudinal study utilizing the recently developed pediatric MRE-based multi-item measure of inflammation (PICMI) to examine the efficacy of adalimumab (ADA) and immunomodulator (IM) in attaining improvement of transmural inflammation of the small intestine.

Methods

Pediatric patients with CD involving small bowel and initiating ADA or IM were prospectively enrolled and followed with repeat MRE at 1 year. A single radiologist provided global assessment (RGA) and scored PICMI items (wall thickness, wall diffusion restriction, mural ulcers, comb sign, mesenteric edema) blinded to clinical information and to the timing of MRE. The primary outcome was mild improvement in PICMI at one year without a change in therapy.

Results

Sixty-two eligible patients were enrolled, 26 receiving ADA and 36 IM. On intent to treat basis, a decline in PICMI score of >20 points without change of therapy was observed more frequently in ADA versus IM-treated patients (54% vs 31%, P = .01). By RGA, 71% improved with ADA vs 42% with IM (P = .03). MRE normalization was rare with both treatments (9% vs 6%, P = .62). A change in PICMI of >20 points was confirmed as the best cut off for MRE improvement as assessed by RGA also for the small bowel.

Conclusions

ADA therapy was associated with objective improvement in MRE findings of inflammation more frequently than IM. The low rate of MRE normalization suggests that this is not yet a realistic target with existing therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabCrohn DiseaseMagnetic Resonance ImagingInflammationAnti-Inflammatory AgentsIntestine, SmallImmunomodulating AgentsHumansFemaleMaleProspective StudiesChildAdolescentLongitudinal StudiesTreatment OutcomeMaintenance ChemotherapySeverity of Illness IndexFollow-Up Studies

Stichwörter der Autor:innen

anti-TNF-alphamagnetic resonance enterography indexpediatric Crohn’s diseasepediatric inflammatory Crohn’s diseasetransmural healing

Substanzen

AdalimumabAnti-Inflammatory AgentsImmunomodulating Agents

Autor:innen und Institutionen

  • Gastroenterology and Nutrition Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Department of NEUROFARBA, University of Florence, Florence, Italy.
  • Department of Gastroenterology, Hepatology and Nutrition, IBD Center, The Hospital for Sick Children, Toronto, ON, Canada.
  • Division of Gastroenterology and Nutrition, Department of Pediatrics, Montreal Children's Hospital, Montreal, QC, Canada.
  • Department of Diagnostic and Interventional Radiology, The Hospital for Sick Children, Toronto, ON, Canada.

ORCID-Profile: Luca Scarallo, Peter C Church

Förderung

  • Abbvie

Zitieren

APA

Scarallo, L., McKay, H. E., Schneider, R., Ricciuto, A., Walters, T. D., Greer, M. C., Griffiths, A. M., & Church, P. C. (2025). Improvement of Transmural Inflammation With Adalimumab Versus Immunomodulator Maintenance Therapy in Pediatric Crohn’s Disease: Single-Center Prospective Evaluation Using the Pediatric Inflammatory Crohn’s Magnetic Resonance Enterography Index. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae227

Vancouver

Scarallo L, McKay HE, Schneider R, Ricciuto A, Walters TD, Greer MC, et al. Improvement of Transmural Inflammation With Adalimumab Versus Immunomodulator Maintenance Therapy in Pediatric Crohn’s Disease: Single-Center Prospective Evaluation Using the Pediatric Inflammatory Crohn’s Magnetic Resonance Enterography Index. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae227

BibTeX
@article{Scarallo2025,
  author = {Scarallo, Luca and McKay, Hayley E and Schneider, Rilla and Ricciuto, Amanda and Walters, Thomas D and Greer, Mary-Louise C and Griffiths, Anne M and Church, Peter C},
  title = {Improvement of Transmural Inflammation With Adalimumab Versus Immunomodulator Maintenance Therapy in Pediatric Crohn’s Disease: Single-Center Prospective Evaluation Using the Pediatric Inflammatory Crohn’s Magnetic Resonance Enterography Index},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae227}
}
Kostenlos starten →